Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319
This study is recruiting at 9 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Kidney Diseases
- Kidney Diseases, Chronic
- Urological Diseases
- Glomerulonephritis
- Glomerular Disease
- Glomerulonephritis, IGA
- Glomerulopathy
- Immunoglobulin Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Novartis Pharmaceuticals
- Last updated on ClinicalTrials.gov
- August 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Colorado Kidney Care Nephrology · Denver, CO
Florida · 1
- Nephrology Associates Of Central FL · Orlando, FL
Iowa · 1
- University of Iowa Hospitals and Clinics · Iowa City, IA
New York · 2
- NY Nephrology · Clifton Park, NY
- Icahn School of Medicine at Mount Sinai · New York, NY
Tennessee · 1
- Knoxville Kidney Center Pllc · Brentwood, TN
Texas · 3
- Dallas Renal Group · Dallas, TX
- Dallas Renal Group · Dallas, TX
- Nephro Asso North Illinois Indiana · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.